Cephalon rated hold by Jefferies

Cephalon was rated hold with a $45.00 price target, Jefferies & Co., Inc. analysts David H. Windley and Himanshu Rastogi said, noting the slowed prescription growth of the company's lead product, Provigil. Cephalon shares closed Thursday up $0.02, or 0.05%, at $38.49 on volume of 882,881 shares versus a three-month trailing average of 1,738,150.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.